Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radix Gentianae Macrophyllae, known in Chinese as Qinjiao, is a traditional Chinese medicine (TCM) derived from the dried roots and rhizomes of several species in the *Gentiana* genus, primarily *Gentiana macrophylla* Pall., *Gentiana straminea* Maxim., *Gentiana crassicaulis* Duthie ex Burk., and *Gentiana daurica* Fisch. It has been used for centuries to treat "wind-damp" conditions, including rheumatoid arthritis, joint pain, stroke, and facial paralysis. The primary bioactive constituents are secoiridoid glycosides (such as gentiopicroside, swertiamarin, sweroside, and loganic acid) and triterpenoids (like roburic acid). Pharmacological studies indicate anti-inflammatory, analgesic, hepatoprotective, and neuroprotective effects, often mediated through the inhibition of NF-κB signaling and modulation of central nervous system receptors like GABA and 5-HT1A.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on radix gentianae macrophyllae.